NASDAQ:TTNP - Titan Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.2350 0.00 (0.00 %) (As of 01/18/2019 04:00 PM ET)Previous Close$0.2350Today's Range$0.22 - $0.2452-Week Range$0.17 - $1.45Volume2.14 million shsAverage Volume1.56 million shsMarket Capitalization$17.93 millionP/E Ratio-0.34Dividend YieldN/ABeta0.48 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California. Receive TTNP News and Ratings via Email Sign-up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTNP Previous Symbol CUSIPN/A Webwww.titanpharm.com Phone650-244-4990Debt Debt-to-Equity Ratio0.76 Current Ratio5.24 Quick Ratio4.65Price-To-Earnings Trailing P/E Ratio-0.34 Forward P/E Ratio-0.71 P/E GrowthN/A Sales & Book Value Annual Sales$220,000.00 Price / Sales83.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book5.88Profitability EPS (Most Recent Fiscal Year)($0.70) Net Income$-14,300,000.00 Net Margins-168.73% Return on Equity-878.37% Return on Assets-119.79%Miscellaneous Employees13 Outstanding Shares77,970,000Market Cap$17.93 million OptionableOptionable Titan Pharmaceuticals (NASDAQ:TTNP) Frequently Asked Questions What is Titan Pharmaceuticals' stock symbol? Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP." How were Titan Pharmaceuticals' earnings last quarter? Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its quarterly earnings results on Wednesday, November, 14th. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The specialty pharmaceutical company had revenue of $1.65 million for the quarter, compared to analysts' expectations of $0.10 million. Titan Pharmaceuticals had a negative net margin of 168.73% and a negative return on equity of 878.37%. View Titan Pharmaceuticals' Earnings History. When is Titan Pharmaceuticals' next earnings date? Titan Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Titan Pharmaceuticals. What price target have analysts set for TTNP? 1 equities research analysts have issued 1 year price objectives for Titan Pharmaceuticals' stock. Their predictions range from $2.00 to $2.00. On average, they expect Titan Pharmaceuticals' share price to reach $2.00 in the next twelve months. This suggests a possible upside of 751.1% from the stock's current price. View Analyst Price Targets for Titan Pharmaceuticals. What is the consensus analysts' recommendation for Titan Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Titan Pharmaceuticals. Has Titan Pharmaceuticals been receiving favorable news coverage? News coverage about TTNP stock has trended extremely positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Titan Pharmaceuticals earned a news sentiment score of 4.3 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next several days. Are investors shorting Titan Pharmaceuticals? Titan Pharmaceuticals saw a decline in short interest in the month of December. As of December 14th, there was short interest totalling 4,111,193 shares, a decline of 28.4% from the November 30th total of 5,745,482 shares. Based on an average daily volume of 2,932,458 shares, the short-interest ratio is presently 1.4 days. Currently, 5.5% of the company's stock are short sold. View Titan Pharmaceuticals' Current Options Chain. Who are some of Titan Pharmaceuticals' key competitors? Some companies that are related to Titan Pharmaceuticals include BioCardia (BCDA), Outlook Therapeutics (OTLK), AVITA MED LTD/S (AVMXY), Applied Genetic Technologies (AGTC), Genocea Biosciences (GNCA), Proteon Therapeutics (PRTO), Arsanis (ASNS), Oncobiologics (ONS), Entera Bio (ENTX), Curis (CRIS), TRACON Pharmaceuticals (TCON), BIONDVAX PHARMA/S (BVXV), Microbot Medical (MBOT), Vical (VICL) and CytRx (CYTR). Who are Titan Pharmaceuticals' key executives? Titan Pharmaceuticals' management team includes the folowing people: Dr. Marc Rubin, Exec. Chairman (Age 64)Mr. Sunil Bhonsle, CEO, Pres, Principal Financial Officer & Director (Age 69)Dr. Katherine L. Beebe-Devarney Ph.D., Exec. VP & Chief Scientific OfficerMr. Dane D. Hallberg, Exec. VP & Chief Commercial OfficerBrian E. Crowley, VP of Fin. Who are Titan Pharmaceuticals' major shareholders? Titan Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.30%). Company insiders that own Titan Pharmaceuticals stock include James R Mcnab, Marc Rubin and Sunil Bhonsle. View Institutional Ownership Trends for Titan Pharmaceuticals. Which major investors are buying Titan Pharmaceuticals stock? TTNP stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Titan Pharmaceuticals stock in the last two years include James R Mcnab, Marc Rubin and Sunil Bhonsle. View Insider Buying and Selling for Titan Pharmaceuticals. How do I buy shares of Titan Pharmaceuticals? Shares of TTNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Titan Pharmaceuticals' stock price today? One share of TTNP stock can currently be purchased for approximately $0.2350. How big of a company is Titan Pharmaceuticals? Titan Pharmaceuticals has a market capitalization of $17.93 million and generates $220,000.00 in revenue each year. The specialty pharmaceutical company earns $-14,300,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Titan Pharmaceuticals employs 13 workers across the globe. What is Titan Pharmaceuticals' official website? The official website for Titan Pharmaceuticals is http://www.titanpharm.com. How can I contact Titan Pharmaceuticals? Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The specialty pharmaceutical company can be reached via phone at 650-244-4990 or via email at [email protected] MarketBeat Community Rating for Titan Pharmaceuticals (NASDAQ TTNP)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 202 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 396MarketBeat's community ratings are surveys of what our community members think about Titan Pharmaceuticals and other stocks. Vote "Outperform" if you believe TTNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTNP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What are defining characteristics of a correction?